
|Articles|April 11, 2008
Inhalable insulin prescribing information revised to include lung malignancy occurrence
Pfizer revises package insert after reports of lung cancer in patients receiving their inhaled insulin.
Advertisement
Pfizer has issued letters to both healthcare professionals and patients to inform them of six reported cases of newly diagnosed primary lung malignancy during clinical trials in patients using their insulin human [rDNA origin] inhalation powder (
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Embedded Pharmacists Are Vital Yet Underutilized in Diabetes Care
2
Executive Order Calls for Realignment of Childhood Vaccines
3
The Prodigious PBM Pivot: How Supply Chain Entities Will Move Forward After CAA 2026
4
Heat and Older Adults: What Pharmacists Need to Know
5





























































